Campbell & CO Investment Adviser LLC Invests $249,000 in Boston Scientific Corporation $BSX

Campbell & CO Investment Adviser LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,318 shares of the medical equipment provider’s stock, valued at approximately $249,000.

A number of other large investors have also added to or reduced their stakes in the company. Sound Income Strategies LLC raised its holdings in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. 1248 Management LLC bought a new position in Boston Scientific during the first quarter valued at approximately $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter worth approximately $27,000. Princeton Global Asset Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Boston Scientific by 72.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on BSX. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Robert W. Baird boosted their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $123.77.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 175,782 shares of company stock valued at $17,742,314 in the last ninety days. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX opened at $101.71 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $150.78 billion, a price-to-earnings ratio of 54.39, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The stock has a fifty day simple moving average of $99.59 and a two-hundred day simple moving average of $102.55. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the firm earned $0.63 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.